VYNE Therapeutics (NASDAQ:VYNE) Earns Buy Rating from HC Wainwright

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $5.75 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 108.33% from the company’s previous close.

Separately, BTIG Research assumed coverage on VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 target price on the stock.

VYNE Therapeutics Stock Performance

Shares of VYNE stock opened at $2.76 on Tuesday. The stock has a market capitalization of $40.71 million, a price-to-earnings ratio of -3.21 and a beta of 1.30. VYNE Therapeutics has a one year low of $1.57 and a one year high of $4.30. The company’s 50-day simple moving average is $2.98 and its 200-day simple moving average is $2.35.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th biggest position. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent quarter. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.